Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Advantages in Prognosis of Adult Patients with Ewing Sarcoma: 11-years Experiences and Current Treatment Management

DA. Krakorova, K. Kubackova, L. Dusek, T. Tomas, P. Janicek, S. Tucek, J. Prausova, I. Kiss, I. Zambo,

. 2018 ; 24 (3) : 623-630. [pub] 20170812

Language English Country Netherlands

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc19001209

Ewing sarcoma (ES) is an exceptionally rare tumor in adults. Data regarding outcomes of adult patients with ES and experiences with age-adapted therapeutic strategies are very limited. The aim of this study was to evaluate prognostic factors and clinical outcome in a cohort of adult patients treated according to pediatric protocols in the Czech Republic. The records of 58 adult ES patients diagnosed between 2002 and 2013 were reviewed and factors relevant to prognosis and survival were analyzed. The median age of study cohort was 29 years (range, 18-59). The most frequent location was axial (36.2%), followed by involvement of extraskeletal tissues (34.5%) and bones of the extremities (29.3%). Twenty-eight (48.3%) patients had metastatic disease. In cases with localized ES, the 5-year overall survival (OS) was 76.5%. Using the log-rank test, the presence of metastasis at diagnosis, local treatment without surgery and a failure to achieve complete remission were associated with significantly shorter survival. In a multivariate Cox proportional hazard analysis, the achievement of complete remission was an independent predictor of patients's survival time. Outcomes of adults with localized ES treated according to multimodal pediatric protocols are similar to children. The achievement of complete remission is an independent predictor of survival time in ES patients. Severe hematological toxicity is foreseeable and manageable. Prognosis of patients with metastases or progression remains dismal.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19001209
003      
CZ-PrNML
005      
20240206091012.0
007      
ta
008      
190107s2018 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s12253-017-0291-6 $2 doi
035    __
$a (PubMed)28803261
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Adámková Krákorová, Dagmar $u Clinic of Comprehensive Cancer Care of Masaryk Memorial Cancer Institute, Brno, Czech Republic. $7 xx0084127
245    10
$a Advantages in Prognosis of Adult Patients with Ewing Sarcoma: 11-years Experiences and Current Treatment Management / $c DA. Krakorova, K. Kubackova, L. Dusek, T. Tomas, P. Janicek, S. Tucek, J. Prausova, I. Kiss, I. Zambo,
520    9_
$a Ewing sarcoma (ES) is an exceptionally rare tumor in adults. Data regarding outcomes of adult patients with ES and experiences with age-adapted therapeutic strategies are very limited. The aim of this study was to evaluate prognostic factors and clinical outcome in a cohort of adult patients treated according to pediatric protocols in the Czech Republic. The records of 58 adult ES patients diagnosed between 2002 and 2013 were reviewed and factors relevant to prognosis and survival were analyzed. The median age of study cohort was 29 years (range, 18-59). The most frequent location was axial (36.2%), followed by involvement of extraskeletal tissues (34.5%) and bones of the extremities (29.3%). Twenty-eight (48.3%) patients had metastatic disease. In cases with localized ES, the 5-year overall survival (OS) was 76.5%. Using the log-rank test, the presence of metastasis at diagnosis, local treatment without surgery and a failure to achieve complete remission were associated with significantly shorter survival. In a multivariate Cox proportional hazard analysis, the achievement of complete remission was an independent predictor of patients's survival time. Outcomes of adults with localized ES treated according to multimodal pediatric protocols are similar to children. The achievement of complete remission is an independent predictor of survival time in ES patients. Severe hematological toxicity is foreseeable and manageable. Prognosis of patients with metastases or progression remains dismal.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a nádory kostí $x patologie $x terapie $7 D001859
650    _2
$a kombinovaná terapie $7 D003131
650    _2
$a management nemoci $7 D019468
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a nádory plic $x sekundární $x terapie $7 D008175
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prognóza $7 D011379
650    _2
$a Ewingův sarkom $x patologie $x terapie $7 D012512
650    _2
$a míra přežití $7 D015996
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kubackova, Katerina $u Second Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. Department of Oncology, Motol University Hospital, Prague, Czech Republic.
700    1_
$a Dusek, Ladislav $u Institute of Biostatistics and Analyses, Faculty of Medicine and Faculty of Science, Masaryk University, Brno, Czech Republic.
700    1_
$a Tomas, Tomas $u First Orthopedic Department, St. Anne's University Hospital, Brno, Czech Republic.
700    1_
$a Janicek, Pavel $u First Orthopedic Department, St. Anne's University Hospital, Brno, Czech Republic.
700    1_
$a Tucek, Stepan $u Clinic of Comprehensive Cancer Care of Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Prausova, Jana $u Second Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. Department of Oncology, Motol University Hospital, Prague, Czech Republic.
700    1_
$a Kiss, Igor $u Clinic of Comprehensive Cancer Care of Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Zambo, Iva $u First Department of Pathological Anatomy, St. Anne's University Hospital, Pekarska 53, 656 91, Brno, Czech Republic. iva.zambo@fnusa.cz.
773    0_
$w MED00180530 $t Pathology oncology research $x 1532-2807 $g Roč. 24, č. 3 (2018), s. 623-630
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28803261 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20240206091009 $b ABA008
999    __
$a ok $b bmc $g 1365106 $s 1039332
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 24 $c 3 $d 623-630 $e 20170812 $i 1532-2807 $m Pathology oncology research $n Pathol Oncol Res $x MED00180530
LZP    __
$a Pubmed-20190107

Find record

Citation metrics

Archiving options